These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 11868865)
1. Present status of various inotropic agents in heart failure. Mittal SR; Maheshwari N J Assoc Physicians India; 2001 Nov; 49():1095-9. PubMed ID: 11868865 [No Abstract] [Full Text] [Related]
2. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
3. [Current role of non-digitalis inotropic agents in acute and chronic treatment of heart failure]. Dei Cas L; Nodari S; Raddino R; Metra M; Pelà G; Nardi M Cardiologia; 1994 Mar; 39(3):209-15. PubMed ID: 8039201 [No Abstract] [Full Text] [Related]
4. [Inotropic agents in advanced and refractory heart failure]. Mangiavacchi M; Gronda E Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928 [No Abstract] [Full Text] [Related]
5. [Positive inotropic agents in heart failure. Clinico-pharmacological evidence for medical practice]. Rohde LE; Ribeiro JP Arq Bras Cardiol; 1994 Dec; 63(6):537-42. PubMed ID: 7605243 [No Abstract] [Full Text] [Related]
12. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D; Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942 [TBL] [Abstract][Full Text] [Related]
13. Prognosis assessment in patients with decompensated heart failure. Simple clinical parameters or neurohormonal factors. Aronson D; Burger AJ Ital Heart J; 2004 Jul; 5(7):494-7. PubMed ID: 15487265 [No Abstract] [Full Text] [Related]
14. [Is heart rate reduction beneficial to patients with heart insufficiency? Focus on beta-blockade]. Henriksen OM; Gadsbøll N Ugeskr Laeger; 2002 Jan; 164(5):615-9. PubMed ID: 11871210 [TBL] [Abstract][Full Text] [Related]
15. Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience. Pacher R; Stanek B Eur J Heart Fail; 1999 Aug; 1(3):263-8. PubMed ID: 10935673 [No Abstract] [Full Text] [Related]
16. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Stevenson LW Circulation; 2003 Jul; 108(4):492-7. PubMed ID: 12885733 [No Abstract] [Full Text] [Related]
17. Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. Felker GM; O'connor CM Am Heart J; 2001 Dec; 142(6):932-3. PubMed ID: 11717593 [No Abstract] [Full Text] [Related]
18. Severe heart failure: balancing length and quality of life. Harv Heart Lett; 1999 Jun; 9(10):1-2. PubMed ID: 10233785 [No Abstract] [Full Text] [Related]